[go: up one dir, main page]

DK3380495T3 - Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi - Google Patents

Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi Download PDF

Info

Publication number
DK3380495T3
DK3380495T3 DK16867488.5T DK16867488T DK3380495T3 DK 3380495 T3 DK3380495 T3 DK 3380495T3 DK 16867488 T DK16867488 T DK 16867488T DK 3380495 T3 DK3380495 T3 DK 3380495T3
Authority
DK
Denmark
Prior art keywords
peptide
receptor
cancer
treatment
conjugates
Prior art date
Application number
DK16867488.5T
Other languages
English (en)
Inventor
Richard Beliveau
Borhane Annabi
Michel Demeule
Alain Larocque
Jean-Christophe Currie
Cyndia Charfi
Original Assignee
Transfert Plus Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus Sec filed Critical Transfert Plus Sec
Application granted granted Critical
Publication of DK3380495T3 publication Critical patent/DK3380495T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083Neurotensin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK16867488.5T 2015-11-24 2016-11-24 Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi DK3380495T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259178P 2015-11-24 2015-11-24
PCT/CA2016/051379 WO2017088058A1 (en) 2015-11-24 2016-11-24 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Publications (1)

Publication Number Publication Date
DK3380495T3 true DK3380495T3 (da) 2021-08-16

Family

ID=58762819

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16867488.5T DK3380495T3 (da) 2015-11-24 2016-11-24 Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi

Country Status (14)

Country Link
US (3) US11034727B2 (da)
EP (2) EP3925969A1 (da)
JP (2) JP6810146B2 (da)
CN (2) CN116478245A (da)
AU (2) AU2016358324B2 (da)
BR (1) BR112018010535A2 (da)
CA (2) CA3071494C (da)
DK (1) DK3380495T3 (da)
ES (1) ES2882634T3 (da)
PL (1) PL3380495T3 (da)
PT (1) PT3380495T (da)
SI (1) SI3380495T1 (da)
WO (1) WO2017088058A1 (da)
ZA (1) ZA201804117B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3380495T3 (da) * 2015-11-24 2021-08-16 Transfert Plus Sec Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi
WO2018213928A1 (en) * 2017-05-24 2018-11-29 Transfert Plus, S.E.C. Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
EP3759144A1 (en) * 2018-03-01 2021-01-06 Glycotope GmbH Fusion protein constructs comprising an anti-muc1 antibody and il-15
CN113286820A (zh) * 2018-08-24 2021-08-20 特拉斯福特普拉斯公司 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物
EP3986921A2 (en) * 2019-06-20 2022-04-27 Aarhus Universitet Sorcs2 crystal structure and uses thereof
CA3160722A1 (en) * 2019-12-06 2021-06-10 Theratechnologies Inc. Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer
US20230338555A1 (en) * 2020-05-18 2023-10-26 Ionis Pharmaceuticals, Inc. Conjugated oligonucleotides and uses thereof
CA3208147A1 (en) * 2021-02-26 2022-09-01 Richard Beliveau Methods and compounds for targeting cancer stem cells
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
WO2024103161A1 (en) * 2022-11-14 2024-05-23 Theratechnologies Inc. Drug conjugate compounds for stimulating the antitumor immune response
CN117904303B (zh) * 2024-03-18 2024-06-18 湖南宏雅基因技术有限公司 Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
FI101678B1 (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
CN1483041A (zh) 2000-12-07 2004-03-17 Glp-1融合蛋白
US8344211B2 (en) 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides
TW200634019A (en) 2004-12-21 2006-10-01 Wyeth Corp Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors
EP2037948B1 (en) 2006-05-30 2016-04-13 Mayo Foundation For Medical Education And Research Detecting and treating dementia
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
KR101614558B1 (ko) * 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
US20120039865A1 (en) * 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2011082290A2 (en) 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
DK3380495T3 (da) * 2015-11-24 2021-08-16 Transfert Plus Sec Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi
WO2018213928A1 (en) * 2017-05-24 2018-11-29 Transfert Plus, S.E.C. Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
CN113286820A (zh) * 2018-08-24 2021-08-20 特拉斯福特普拉斯公司 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物

Also Published As

Publication number Publication date
EP3380495A4 (en) 2019-02-27
CA3006313C (en) 2020-02-11
EP3380495B1 (en) 2021-05-19
WO2017088058A1 (en) 2017-06-01
US20200392184A1 (en) 2020-12-17
JP7095035B2 (ja) 2022-07-04
US20220356209A1 (en) 2022-11-10
SI3380495T1 (sl) 2022-01-31
AU2021201085B2 (en) 2023-01-19
US11780882B2 (en) 2023-10-10
CA3071494C (en) 2021-12-14
CA3006313A1 (en) 2017-06-01
ES2882634T3 (es) 2021-12-02
CN116478245A (zh) 2023-07-25
PT3380495T (pt) 2021-08-19
JP2020189867A (ja) 2020-11-26
US20240199695A1 (en) 2024-06-20
US11034727B2 (en) 2021-06-15
AU2016358324B2 (en) 2021-03-11
JP2019501141A (ja) 2019-01-17
CN108473541A (zh) 2018-08-31
AU2016358324A1 (en) 2018-07-05
CA3071494A1 (en) 2017-06-01
JP6810146B2 (ja) 2021-01-06
AU2021201085A1 (en) 2021-03-11
CN108473541B (zh) 2023-05-12
ZA201804117B (en) 2022-08-31
EP3925969A1 (en) 2021-12-22
BR112018010535A2 (pt) 2018-11-13
EP3380495A1 (en) 2018-10-03
PL3380495T3 (pl) 2021-12-13

Similar Documents

Publication Publication Date Title
DK3380495T3 (da) Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
EP3651772A4 (en) ANTI-CANCER POLYTHERAPY
DK3319993T3 (da) AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
DK3474841T3 (da) Fremgangsmåder til behandling af ar+-brystkræft
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3430038T3 (da) Sammensætninger og fremgangsmåder til cd20-immunterapi
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3622953T3 (da) Kombinationsbehandling af cancer
EP3474854A4 (en) DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
DK3518932T3 (da) Behandling af prostatacancer
DK3353177T3 (da) Tricykliske heterocykler til behandling af cancer
EP3413927A4 (en) CANCER THERAPY
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK3400072T3 (da) Formuleringer til behandling af blærecancer
DK3638293T5 (da) Sammensætninger til behandling af cancer
DK3576740T3 (da) Cancerbehandling
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui